Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205388 | 1.00 | NAMPT (1.00) | NAMPTTYMS | |
| SCHEMBL31181450 | 1.00 | NAMPT (1.00) | NAMPTTYMS | |
| SCHEMBL6583674 | 0.96 | NAMPT (0.93) | NAMPTTYMS | |
| SCHEMBL6582323 | 0.95 | NAMPT (0.91) | NAMPTTYMS | |
| SCHEMBL6580678 | 0.95 | NAMPT (0.90) | NAMPTTYMS | |
| SCHEMBL6580696 | 0.95 | NAMPT (0.90) | NAMPTTYMS | |
| SCHEMBL16286377 | 0.94 | NAMPT (1.00) | NAMPTTYMS | |
| SCHEMBL6580609 | 0.94 | NAMPT (0.88) | NAMPTTYMS | |
| SCHEMBL6584636 | 0.93 | NAMPT (0.87) | NAMPTTYMS | |
| SCHEMBL6584218 | 0.93 | NAMPT (0.87) | NAMPTTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021102420-A1 | INTERFERON SIGNALING AS A CANCER BIOMARKER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | claimed |
| EP-1155012-B1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2004-04-14 | — | — | EP | claimed |
| US-6699861-B1 | ANTI-CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-02 | — | — | US | claimed |
| JP-2002537391-A | — | — | 2002-11-05 | — | — | JP | claimed |
| EP-1155012-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | Cancer Research Ventures Limited (GB) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050417-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER RESEARCH VENTURES LIMITED (GB) | 2000-08-31 | — | — | WO | claimed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2021102420-A1 | INTERFERON SIGNALING AS A CANCER BIOMARKER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-1155012-B1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2004-04-14 | — | — | EP | disclosed |
| US-6699861-B1 | ANTI-CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| EP-1155012-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | Cancer Research Ventures Limited (GB) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050417-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER RESEARCH VENTURES LIMITED (GB) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | NAMPT, NAPRT, NNT | NAMPT 1/4885TYMS 219/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | NAMPT 813/4885TYMS 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.